LIGORIO, FRANCESCA
LIGORIO, FRANCESCA
Universita' degli Studi di MILANO
Real-world effectiveness of CDK4/6 inhibitors in older patients with HR+/HER2- advanced breast cancer: a sub-analysis of the multicenter, PALMARES-2 study
2026 F. Ligorio, L. Provenzano, G. Fotia, M.V. Dieci, G. Curigliano, M. Giuliano, A. Botticelli, M. Lambertini, G. Rizzo, R. Pedersini, M. Sirico, N. La Verde, A. Gennari, A. Zambelli, A. Toss, M. Piras, M. Giordano, B. Tagliaferri, D. Generali, D. Sartori, G. Mazzoli, F. Jacobs, G. Armani, C. Sposetti, C. Zurlo, A. Menichetti, G. Griguolo, V. Faso, L. Boldrini, E. Munzone, A. Marra, E. Chiappe, S. Scagnoli, S. Pisegna, C. Capasso, C. De Angelis, G. Arpino, C. Criscitiello, V. Guarneri, G. Pruneri, L. Mariani, C. Vernieri
Effectiveness comparison of first-line CDK4/6 inhibitors in patients with hormone-positive HER2-negative advanced breast cancer according to tumor histology: a sub-analysis of the real-world, multicenter, Italian study PALMARES-2
2026 G. Mazzoli, L. Provenzano, M.V. Dieci, G. Curigliano, M. Giuliano, A. Botticelli, M. Lambertini, G. Rizzo, R. Pedersini, M. Sirico, N. La Verde, A. Gennari, A. Zambelli, A. Toss, M. Piras, M. Giordano, B. Tagliaferri, D. Generali, D. Sartori, G. Fotia, M. De Monte, F. Ligorio, F. Jacobs, G. Armani, C. Zurlo, A. Menichetti, G. Griguolo, V. Faso, A.C. Schianca, E. Munzone, A. Marra, E. Chiappe, S. Scagnoli, S. Pisegna, C. Capasso, C. De Angelis, G. Arpino, C. Criscitiello, V. Guarneri, G. Pruneri, L. Mariani, G. the PALMARES-2 study, C. Vernieri
Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study
2025 L. Provenzano, M.V. Dieci, G. Curigliano, M. Giuliano, A. Botticelli, M. Lambertini, G. Rizzo, R. Pedersini, M. Sirico, N. La Verde, A. Gennari, A. Zambelli, A. Toss, M. Piras, M. Giordano, B. Tagliaferri, D. Generali, D. Sartori, D. Miliziano, A. Menichetti, F. Ligorio, C. Zurlo, G. Griguolo, P.P. Berton Giachetti, V. Faso, C. Corti, E. Chiappe, S. Scagnoli, S. Pisegna, C. Capasso, C. De Angelis, G. Arpino, C. Criscitiello, V. Guarneri, G. Pruneri, L. Mariani, C. Vernieri
Targeting Cyclin-Dependent Kinase 4 Amplifications: A Pioneering Case of Metastatic Leydig Cell Tumor Responding to Abemaciclib
2025 A. Nuzzo, M. Barella, M. Claps, M. Zimatore, A. Rametta, M. Stellato, F. Ligorio, E. Gusmaroli, S. Rota, F. Manoni, M. Colecchia, S. Nazzani, D. Biasoni, T. Cascella, M. Catanzaro, D. Rusconi, C. Vela, C. Silvani, G. Procopio, A. Necchi, N. Nicolai, P. Giannatempo
Cyclic fasting-mimicking diet in cancer treatment: Preclinical and clinical evidence
2024 C. Vernieri, F. Ligorio, D. Tripathy, V.D. Longo
Fasting-mimicking diet: a metabolic approach for the treatment of breast cancer
2023 F. Ligorio, L. Provenzano, C. Vernieri
The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis
2023 L. Provenzano, R. Lobefaro, F. Ligorio, E. Zattarin, L. Zambelli, C. Sposetti, D. Presti, G. Montelatici, A. Ficchì, A. Martinetti, A. Arata, M. Del Vecchio, C. Lauria Pantano, B. Formisano, G.V. Bianchi, G. Capri, F. de Braud, C. Vernieri, G. Fucà
Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors
2023 E. Zattarin, L. Mariani, A. Menichetti, R. Leporati, L. Provenzano, F. Ligorio, G. Fucà, R. Lobefaro, L. Lalli, A. Vingiani, F. Nichetti, G. Griguolo, M. Sirico, O. Bernocchi, A. Marra, C. Corti, P. Zagami, E. Agostinetto, F. Jacobs, P. Di Mauro, D. Presti, C. Sposetti, C.A. Giorgi, V. Guarneri, R. Pedersini, A. Losurdo, D. Generali, G. Curigliano, G. Pruneri, F. de Braud, M.V. Dieci, C. Vernieri
Prognostic impact of body mass index (BMI) in HER2+ breast cancer treated with anti-HER2 therapies: from preclinical rationale to clinical implications
2022 F. Ligorio, L. Zambelli, G. Fucà, R. Lobefaro, M. Santamaria, E. Zattarin, F. de Braud, C. Vernieri
Case Report: Prolonged clinical benefit with sequential trastuzumab-containing treatments in a patient with advanced extramammary Paget disease of the groin
2022 E. Zattarin, F. Nichetti, F. Ligorio, L. Mazzeo, R. Lobefaro, G. Fuca, G. Peverelli, A. Vingiani, G. Bianchi, V, G. Capri, F. de Braud, C. Vernieri
Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer
2022 C. Vernieri, G. Fucà, F. Ligorio, V. Huber, A. Vingiani, F. Iannelli, A. Raimondi, D. Rinchai, G. Frigè, A. Belfiore, L. Lalli, C. Chiodoni, V. Cancila, F. Zanardi, A. Ajazi, S. Cortellino, V. Vallacchi, P. Squarcina, A. Cova, S. Pesce, P. Frati, R. Mall, P.A. Corsetto, A.M. Rizzo, C. Ferraris, S. Folli, M.C. Garassino, G. Capri, G. Bianchi, M.P. Colombo, S. Minucci, M. Foiani, V.D. Longo, G. Apolone, V. Torri, G. Pruneri, D. Bedognetti, L. Rivoltini, F. de Braud
Predictive role of CD36 expression in HER2-positive breast cancer patients receiving neoadjuvant trastuzumab
2022 F. Ligorio, S. Di Cosimo, P. Verderio, C.M. Ciniselli, S. Pizzamiglio, L. Castagnoli, M. Dugo, B. Galbardi, R. Salgado, S. Loi, S. Michiels, T. Triulzi, E. Tagliabue, S. El-Abed, M. Izquierdo, E. de Azambuja, P. Nuciforo, J. Huober, L. Moscetti, W. Janni, M.A. Coccia-Portugal, P.A. Corsetto, A. Belfiore, D. Lorenzini, M.G. Daidone, A. Vingiani, L. Gianni, S.M. Pupa, G. Bianchini, G. Pruneri, C. Vernieri
Exceptional tumour responses to fasting-mimicking diet combined with standard anticancer therapies: A sub-analysis of the NCT03340935 trial
2022 F. Ligorio, G. Fucà, L. Provenzano, R. Lobefaro, L. Zanenga, A. Vingiani, A. Belfiore, A. Lorenzoni, A. Alessi, G. Pruneri, F. de Braud, C. Vernieri
The pan-immune-inflammation-value predicts the survival of patients with human epidermal growth factor receptor 2 (Her2)—positive advanced breast cancer treated with first-line taxane-trastuzumab-pertuzumab
2021 F. Ligorio, G. Fuca, E. Zattarin, R. Lobefaro, L. Zambelli, R. Leporati, C. Rea, G. Mariani, G.V. Bianchi, G. Capri, F. de Braud, C. Vernieri
Impact of pathological stratification on the clinical outcomes of advanced well‐differentiated/dedifferentiated liposarcoma treated with trabectedin
2021 C. Fabbroni, G. Fuca, F. Ligorio, E. Fumagalli, M. Barisella, P. Collini, C. Morosi, A. Gronchi, A.P.D. Tos, P.G. Casali, R. Sanfilippo
Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET)
2021 C. Vernieri, F. Nichetti, L. Lalli, L. Moscetti, C.A. Giorgi, G. Griguolo, A. Marra, G. Randon, C.G. Rea, F. Ligorio, S. Scagnoli, C. De Angelis, C. Molinelli, A. Fabbri, E. Ferraro, D. Trapani, A. Milani, E. Agostinetto, O. Bernocchi, G. Catania, A. Vantaggiato, M. Palleschi, A. Moretti, D. Basile, M. Cinausero, A. Ajazi, L. Castagnoli, S. Lo Vullo, L. Gerratana, F. Puglisi, N. La Verde, G. Arpino, A. Rocca, M. Ciccarese, R. Pedersini, A. Fabi, D. Generali, A. Losurdo, F. Montemurro, G. Curigliano, L. Del Mastro, A. Michelotti, E. Cortesi, V. Guarneri, G. Pruneri, L. Mariani, F. de Braud
Prolonged benefit from palbociclib plus letrozole in heavily pretreated advanced male breast cancer: case report
2021 E. Zattarin, F. Ligorio, F. Nichetti, G. Bianchi, G. Capri, F. de Braud
HER2 signaling and breast cancer stem cells: the bridge behind HER2-positive breast cancer aggressiveness and therapy refractoriness
2021 S.M. Pupa, F. Ligorio, V. Cancila, A. Franceschini, C. Tripodo, C. Vernieri, L. Castagnoli
Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer
2021 F. Ligorio, I. Pellegrini, L. Castagnoli, A. Vingiani, R. Lobefaro, E. Zattarin, M. Santamaria, S.M. Pupa, G. Pruneri, F. de Braud, C. Vernieri
Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients
2021 F. Ligorio, L. Zambelli, A. Bottiglieri, L. Castagnoli, E. Zattarin, R. Lobefaro, A. Ottini, A. Vingiani, S.M. Pupa, G.V. Bianchi, G. Capri, G. Pruneri, F. de Braud, C. Vernieri